Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-negative Breast Cancer × Capecitabine × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 372 Triple Negative Breast Neoplasms 56 Neoplasm Metastasis 47 Neoplasms 18 Breast Neoplasms, Male 12 Brain Neoplasms 12 Colorectal Neoplasms 11 Stomach Neoplasms 10 Pancreatic Neoplasms 10 Inflammatory Breast Neoplasms 6 HER2-positive Breast Cancer 6 Colonic Neoplasms 6 Ovarian Neoplasms 5 Advanced Breast Cancer 5 Squamous Cell Carcinoma of Head and Neck 4 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Carcinoma, Non-Small-Cell Lung 4 Sarcoma 3 Rectal Neoplasms 3 Prostatic Neoplasms 3 Meningeal Neoplasms 3 Lymphoma, Non-Hodgkin 3 HER2 Positive Metastatic Breast Cancer 3 Gallbladder Neoplasms 3 Esophageal Neoplasms 3 Carcinoma, Hepatocellular 3 Breast Cancer Metastatic 3 Small Cell Lung Carcinoma 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Neoplasms, Unknown Primary 2

Interventions

eribulin 2 Vinorelbine 2 Paclitaxel 2 Cyclophosphamide 2 trastuzumab deruxtecan 1 taxane 1 sacituzumab govitecan 1 pembrolizumab 1 pamiparib 1 liposomal doxorubicin 1 camrelizumab 1 Precision Medicine 1 Gemcitabine 1 Epirubicin 1 Doxorubicin 1 Docetaxel 1 Cisplatin 1 Carboplatin 1 Capecitabine 1 Anthracyclines 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06102824 2024-11-25

ORIENTA

Guangdong Provincial People's Hospital

Phase 2 Recruiting

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡